All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Vaccination to Alzheimer disease. Is it a promising tool or a blind way?

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F60162694%3AG44__%2F16%3A43875597" target="_blank" >RIV/60162694:G44__/16:43875597 - isvavai.cz</a>

  • Alternative codes found

    RIV/62156489:43410/16:43909724

  • Result on the web

    <a href="http://www.eurekaselect.com/141335/article" target="_blank" >http://www.eurekaselect.com/141335/article</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.2174/0929867323666160418114733" target="_blank" >10.2174/0929867323666160418114733</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Vaccination to Alzheimer disease. Is it a promising tool or a blind way?

  • Original language description

    Alzheimer disease (AD) is an irreversible neurodegenerative disorder associated with cognitive dysfunction. The disease incidence has growing tendency worldwide with strong impact on healthcare funds. The fact that there is no effective therapy makes the disorder more serious. Currently, AD manifestation can be suppressed by having impact on enzyme acetylcholinesterase: donepezil, rivastigmine, and galantamine or ionotropic glutamate NMDA receptor (memanitine). Contrary to the drugs effecting symptomatically, vaccination against amyloid plaques or neurofibrillary tangles and their precursors amyloid beta and hyperphosphorylated tau are expected to be more suitable. Huge numbers of works have been done on the issue. Unfortunately, the promising vaccines like the AN 1792 were halted during clinical trials because of adverse effects like meningoencephalitis. Monoclonal antibody specific to amyloid plaques, Bapineuzumab, was closest to the practical performance but the clinical trials were also stopped. The review summarizes facts about AD, opportunities in AD vaccination, and obstacles that limit the vaccination including reasons why the recent trials have fallen.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FR - Pharmacology and apothecary chemistry

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Others

  • Publication year

    2016

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Current Medicinal Chemistry

  • ISSN

    0929-8673

  • e-ISSN

  • Volume of the periodical

    23

  • Issue of the periodical within the volume

    14

  • Country of publishing house

    AE - UNITED ARAB EMIRATES

  • Number of pages

    10

  • Pages from-to

    1432-1441

  • UT code for WoS article

    000376451500003

  • EID of the result in the Scopus database